Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis


A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis




This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.

Study Status: Completed


Condition Intervention Phase
Multiple Sclerosis Drug: rituximab Phase 2

Verified by Genentech September, 2009

Sponsored by: Genentech
Information provided by: Genentech identifier: NCT00097188

Study Type: Interventional

Study Design: Primary Purpose: Treatment

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Craig Smith, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site